HIV / AIDS in the News

Childhood HBV Vaccination May Reduce HBV Coinfection in People With HIV - Infectious Disease Advisor

 

Once-Weekly Oral HIV Regimen Matches Daily Therapy in Phase 3 Trials - Infectious Disease Special Edition

 

World Hepatitis Day 2026: Hepatitis: Let’s Break It Down - European AIDS Treatment Group

 

Activists Disrupt Global AIDS Conference to Protest Trump’s Attack on HIV Funding - POZ

 

[AIDS 2026] Johns Hopkins Bloomberg School of Public Health: Lancet report recommends paradigm shift in care for older adults with HIV - European AIDS Treatment Group

 

Beyond blocking HIV: How tenofovir shapes the immune system - Fred Hutchinson Cancer Center

 

[AIDS 2026] [Report] KFF/UNAIDS: Donor government funding for HIV drops by $2.1 billion in 2025 - European AIDS Treatment Group

 

HIV progress in ‘real danger’ as global funding plummets - The Japan Times

 

Lancet Report Recommends Paradigm Shift in Care for Older Adults with HIV | Newswise - Newswise

 

[AIDS 2026] [Press release] ViiV Healthcare’s 2-drug regimen Dovato is as effective as 3-drug regimen Biktarvy in first-of-its-kind head-to-head study in treatment-naïve adults living with HIV - European AIDS Treatment Group

 

World risks HIV resurgence as funding falls 18 per cent, UNAIDS says - sightmagazine.com.au

 

World risks HIV resurgence as funding falls 18%, UNAIDS says - Reuters

 

In HelloNation, Healthcare Expert Kim McKenna Breaks Down HIV and Hepatitis Care in Rural Kentucky - PR Newswire

 

HIV/AIDS Research, Innovation Persist Despite PEPFAR Funding Cuts - The Washington Informer

 

Updating the tools needed to fight an evolving HIV - Fred Hutchinson Cancer Center

 

Merck (MRK) Is Up 5.4% After Expanding HIV PrEP Access And Launching Oral Cholesterol Drug - Yahoo Finance

 

Dovato Shows Noninferior Efficacy to Biktarvy in Head-to-Head HIV Trial - Contagion Live

 

HIV resurgence is feared as global funding to combat the disease falls 18% - STAT

 

Head-to-head study shows Dovato as effective as Biktarvy in HIV | AIDS 2026 - Managed Healthcare Executive

 

Twice-Yearly Lenacapavir Maintains High PrEP Efficacy in PURPOSE Extensions - Infectious Disease Special Edition

 

HIV prevention progress depends on resilience and practical choices - Managed Healthcare Executive

 

US Drives 25% Plunge In HIV Funding In 2025 - Health Policy Watch

 

Musk passed ‘slow death sentence’ on HIV patients by cutting US spending, says head of UNAIDS - The Telegraph

 

Trump aid cuts put HIV response at risk, reports show - The Hill

 

ViiV’s Dovato matches Biktarvy in HIV treatment study - Investing.com

 

Lancet Report Recommends Paradigm Shift in Care for Older Adults with HIV - Johns Hopkins Bloomberg School of Public Health

 

Pennsylvania ends enhanced criminal penalties for people living with HIV - LGBTQ Nation

 

ViiV Healthcare’s 2-drug regimen Dovato is as effective as 3-drug regimen Biktarvy in first-of-its-kind head-to-head study in treatment-naïve adults living with HIV - Business Wire

 

CMS' obstetric G-codes draw concern, HIV screening recommendation strengthened, Roche's BV/CV assay clearance - Contemporary OB/GYN

 

Trump Cuts to HIV Prevention Hurt Ohio Groups - Columbus Underground